Epoetin alfa's effect on left ventricular hypertrophy and subsequent mortality

Area of Science:

• Cardiology
• Nephrology
• Hematology

Background:

• Left ventricular hypertrophy (LVH) is prevalent in patients with chronic renal failure (CRF) and congestive heart failure (CHF).
• The association between LVH and mortality in these patients requires further investigation.
• No prior meta-analyses have comprehensively examined the impact of anemia treatment on LVH and subsequent mortality in CRF and CHF patients.

Purpose of the Study:

• To conduct a meta-analysis examining the effects of anemia treatment on LVH in patients with CRF and CHF.
• To investigate the association between LVH and mortality in this patient population.
• To evaluate the potential survival benefits of epoetin alfa therapy.

Main Methods:

• Systematic literature searches were performed on MEDLINE, EMBASE, and OVID.
• Two meta-analyses were conducted: one on epoetin alfa, anemia, and LVH parameters, and another on LVH and mortality.
• Risk models were utilized to assess the association between LVH and mortality.

Main Results:

• Epoetin alfa treatment led to increased hemoglobin (Hb) and hematocrit (Hct), and decreased left ventricular mass (LVM) and LVM index.
• Ejection fraction (EF) increased, while left ventricular end-diastolic and end-systolic volumes decreased.
• LVH was strongly associated with a two- to three-fold increase in both cardiovascular and all-cause mortality.

Conclusions:

• Anemia amelioration with epoetin alfa therapy reduces key LVH parameters in patients with CRF and CHF.
• Regression of LVM is associated with reduced cardiovascular morbidity and mortality.
• Epoetin alfa therapy may offer a survival advantage for patients with CRF and CHF by addressing anemia and reducing LVH.